MEA Enteral Feeding Formulas Market

MEA Enteral Feeding Formulas Market Size (2023 to 2028)

As per the research report, the size of the Middle East and Africa Enteral Feeding Devices Market is valued at USD 0.81 Billion in 2023.  It is further estimated to be growing at a CAGR of 7.43%, to reach USD 1.16 Billion by 2028. A growing number of hospitals and ambulatory care services embrace enteral nutrition as an effective system of clinical nutrition.

The increased prevalence of chronic diseases and disorders in MEA is one of the key factors driving enteral feeding formulas. In addition, the rising number of preterm births and the number of home health agencies and nursing homes are increasing the demand for facilities that help patients recover from surgery.

The Middle East and Africa are projected to provide market participants with substantial growth prospects during the forecast period. This is owing to the countries' various healthcare markets, the rising prevalence of infectious and chronic diseases, and more outstanding R&D efforts to develop breakthrough medical technology.

Furthermore, population growth, healthcare infrastructure development, increasing healthcare expenditure, and an increase in the senior population benefit the enteral feeding formulae market. Moreover, the surge in demand for customized medication creates profitable prospects for market players from 2023 to 2028.

Enteral nutrition is a convenient and cost-effective way to provide therapeutic nourishment to patients. However, there are a few disadvantages to employing these devices, including increased healthcare costs. Most enteral feeding problems are minor, but a few can be rather severe. Enteral nutrition metabolic issues are similar to those that emerge with parenteral nutrition, despite their lower prevalence and severity. Careful monitoring can help to reduce or prevent these problems. However, these concerns and the risk of death connected with these issues act as a deterrent to the widespread adoption of enteral feeding devices.

This research report on the Middle East and Africa enteral feeding formulas market has been segmented and sub-segmented into the following categories:

By Product: 

• Polymeric
• Monomeric
• Disease-Specific Formulas

By Stage: 

• Adults
• Pediatrics

By Application: 

• Oncology
• Gastroenterology
• Neurology

By End User: 

• Hospitals
• LTCS
• Home Care

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa enteral feeding formulas market had a moderate proportion of the global market in 2020, with the UAE and Kuwait playing a significant role in the MEA enteral feeding formulas market. However, increased demand for home care and an increase in chronic illness occurrences such as multiple sclerosis, obstructive pulmonary disease (COPD), stroke, chronic liver disease, and diabetes have altered the market in regional countries.

The gastrointestinal tract, which includes the esophagus, stomach, small and large intestines, provides artificial nutrition or medication to the organs. On the other hand, Parenteral feeding entails placing a catheter into the central or peripheral veins and delivering nutrients or medication directly into the bloodstream.

In addition, enteral nutrition is less expensive than parenteral nutrition. The average daily cost of enteral nutrition is roughly 40% cheaper than that of parenteral nourishment for a patient. Enteral feeding is currently commonly employed in several treatment regimens due to these benefits.

Furthermore, improvements in healthcare infrastructure, rising healthcare expenditures, and the expanding low-cost manufacturing advantage of MEA countries are expected to tempt market participants to invest in the region during the forecast period.

KEY MARKET PLAYERS:

A few of the companies playing an influential role in the MEA Enteral Feeding Formulas Market profiled in the report are Abbott Laboratories (U.S.), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi AG (Germany), Mead Johnson Nutrition Company (U.S.), B. Braun Melsungen AG (Germany), Hormel Foods, LLC (U.S.), Victus Inc. (U.S.), Meiji Holdings Co., Ltd. (Japan), and Global Health Product Inc. (U.S.).